Margaret A. Connors

Supplementary Figure 1 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts

Jianxiong Ji, Sonja Dragojevic, Cameron M. Callaghan, Emily J. Smith et autres

Supplemental Figure 1 shows bar graph of quantification of cells that have >25 gH2AX foci per cell in M15 cell line, after treatment with peposertib and radiation

Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts

Jianxiong Ji, Sonja Dragojevic, Cameron M. Callaghan, Emily J. Smith et autres

Supplemental Figure 2 shows bar graph of quantification of cells that have >25 gH2Ax foci per cell in M27 cell line, after treatment with peposertib and radiation

Supplementary Materials and Methods from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts

Jianxiong Ji, Sonja Dragojevic, Cameron M. Callaghan, Emily J. Smith et autres

Supplementary Materials and Data show the cell culture and western blot data

Supplemental Figure 3 from DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits

Sonja Dragojevic, Emily J. Smith, Michael S. Regan, Sylwia A. Stopka et autres

Standardization curve of peposertib (M3814) concentration as measured by MALDI in normal and tumor tissue.

Supplemental Figure 2 from DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits

Sonja Dragojevic, Emily J. Smith, Michael S. Regan, Sylwia A. Stopka et autres

Top row: Correlation of Normalized Enrichment Scores (NES) and viability of IR+peposertib normalized to IR in Homologous Recombination (HR), Microhomology-mediated End Joining (MMEJ), Non-Homologous End Joining (NHEJ), and mRNA PRKDC rpkm in four PDX GBM lines (GBM 6, 10, 22, and 76). …

Data from DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits

Sonja Dragojevic, Emily J. Smith, Michael S. Regan, Sylwia A. Stopka et autres

Abstract Glioblastoma (GBM) remains one of the most therapy-resistant malignancies with frequent local failures despite aggressive surgery, chemotherapy, and ionizing radiation (IR). Small molecule inhibitors of DNA-dependent protein kinase (DNA-PKi) are potent radiosensitizers currently in clinical trials. Determining which patients may benefit …

Supplemental Figure 1 from DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits

Sonja Dragojevic, Emily J. Smith, Michael S. Regan, Sylwia A. Stopka et autres

A, Immunoflourescence of 53BP1 foci in U251 cells 1- and 24-hours after indicated treatments. B, PRKDC methylation scores in indicated GBM PDX lines. C, Somatic mutations and Copy Number Variations in GBM PDX lines tested in vivo in key GBM pathways. D, …

Radiation therapy for brain tumors: Does it influence drug delivery?

Wenjuan Zhang, Michael P. Grams, Rajneet K. Oberoi, Ju‐Hee Oh et autres

us (code pays fourni par la source)

The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors

Wenjuan Zhang, Michael P. Grams, Rajneet K. Oberoi, Ju‐Hee Oh et autres

BACKGROUND: Most oncology therapeutics have limited distribution into the brain, and developing strategies to overcome this limitation would be clinically impactful. While therapeutic radiation is often cited as a strategy to accomplish this, there are no published studies demonstrating the effect of …

us (code pays fourni par la source)

Supplementary Figure S1 from Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628

D. Garcia, Sneha Rathi, Margaret A. Connors, Michael P. Grams et autres

Supplementary Figure S1 includes repeats of immunofluorescence images and an example of H&E staining from untreated oral mucosa.

Supplementary Table S1 from Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628

D. Garcia, Sneha Rathi, Margaret A. Connors, Michael P. Grams et autres

Supplementary Table S1: treatment groups, doses, and sample sizes for oral mucosal and esophageal toxicity dose-response studies.

Supplementary Figure S3 from Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628

D. Garcia, Sneha Rathi, Margaret A. Connors, Michael P. Grams et autres

Supplementary Figure S3 shows effect of irradiating different lengths of esophagus. Additionally, higher magnitude images of esophageal H&E images.